GT Biopharma Inc
NASDAQ:GTBP

Watchlist Manager
GT Biopharma Inc Logo
GT Biopharma Inc
NASDAQ:GTBP
Watchlist
Price: 0.832 USD -1.54%
Market Cap: 8.8m USD

Intrinsic Value

The intrinsic value of one GTBP stock under the Base Case scenario is 0.238 USD. Compared to the current market price of 0.832 USD, GT Biopharma Inc is Overvalued by 71%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GTBP Intrinsic Value
0.238 USD
Overvaluation 71%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
GT Biopharma Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about GTBP?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GTBP valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for GT Biopharma Inc.

Explain Valuation
Compare GTBP to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GTBP?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
GT Biopharma Inc

Current Assets 2.7m
Cash & Short-Term Investments 2.4m
Other Current Assets 293k
Current Liabilities 3.6m
Accounts Payable 2.4m
Accrued Liabilities 1.1m
Other Current Liabilities 126k
Efficiency

Free Cash Flow Analysis
GT Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
GT Biopharma Inc

Revenue
0 USD
Operating Expenses
-13.2m USD
Operating Income
-13.2m USD
Other Expenses
1.5m USD
Net Income
-11.7m USD
Fundamental Scores

GTBP Profitability Score
Profitability Due Diligence

GT Biopharma Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional ROIC
Low 3Y Average Gross Margin
Low 3Y Average Net Margin
47/100
Profitability
Score

GT Biopharma Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

GTBP Solvency Score
Solvency Due Diligence

GT Biopharma Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

GT Biopharma Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GTBP Price Targets Summary
GT Biopharma Inc

There are no price targets for GTBP.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

GT Biopharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GTBP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

GTBP Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one GTBP stock?

The intrinsic value of one GTBP stock under the Base Case scenario is 0.238 USD.

Is GTBP stock undervalued or overvalued?

Compared to the current market price of 0.832 USD, GT Biopharma Inc is Overvalued by 71%.

Back to Top